Saterinone
CAS : 102669-89-6
Ref. 3D-CEA66989
5mg | À demander | ||
10mg | À demander | ||
25mg | À demander | ||
50mg | À demander | ||
100mg | À demander |
Informations sur le produit
- Saterinone [INN]
- (+-)-1,2-Dihydro-5-(p-(2-hydroxy-3-(4-(o-methoxyphenyl)-1-piperazinyl)propoxy)phenyl)-6-methyl-2-oxonicotinonitrile
- Saterinona
- Saterinona [Spanish]
- Saterinonum
- Saterinonum [Latin]
- Unii-W4P85Fo7Gs
- 5-(4-{2-Hydroxy-3-[4-(2-Methoxyphenyl)Piperazin-1-Yl]Propoxy}Phenyl)-6-Methyl-2-Oxo-1,2-Dihydropyridine-3-Carbonitrile
Saterinone is a cardiac glycoside that binds to the beta-adrenergic receptor. Saterinone has been shown to reduce the incidence of cancer and bowel disease in rats, as well as the severity of bowel disease. It is also used for the treatment of congestive heart failure and inflammatory bowel disease. This drug has inhibitory properties on isolated heart muscle cells, which are mediated by its ability to bind to the beta-adrenergic receptor. Furthermore, saterinone may have a role in blood pressure monitoring because it inhibits angiotensin II-induced contraction of isolated vascular smooth muscle cells.
Saterinone is an inhibitor of nitroprusside-induced hypotension in rabbits, which may be due to its ability to inhibit nitric oxide synthase (NOS).
Propriétés chimiques
Question d’ordre technique sur : 3D-CEA66989 Saterinone
Si vous souhaitez demander un devis ou passer commande, veuillez plutôt ajouter les produits souhaités à votre panier, puis demander un devis ou passer commande à partir de votre panier. C'est une méthode plus rapide, plus économique, et vous pourrez bénéficier des remises disponibles ainsi que d'autres avantages